Citations

Clear

134 citation(s) found for "Mayo, Kelsey".

No Woman Left Un-Kitted: Is the Traditional Expedition Medical Kit Really Fit for Women?
Oliver, M, Broughton, S, Joyce, Kelsey E.

Mayo Clinic

Wilderness & Environmental Medicine | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10806032261505808 | PMID 42981117 Get It

Patient-Reported Outcomes after Robotic Resection of Deep Endometriosis of the Bowel
Addison, Poppy , Stewart, Kelsey, Garfinkle, Richard , Cope, Adela, Langstraat, Carrie , Burnett, Tatnai, Behm, Kevin

Mayo Clinic

Diseases of the Colon & Rectum | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dcr.0000000000004492 | PMID 42974830 Get It

BACKGROUND: While minimally invasive surgery is the current surgical standard of care for excision of deep endometriosis of the bowel, there is little literature evaluating patient-reported outcome measures following a multidisciplinary, robotic approach. OBJECTIVE: This study aimed to assess the functional outcomes of robotic surgery for patients undergoing resection of deep endometriosis involving the bowel. DESIGN: Retrospective cohort review. SETTINGS: A single academic tertiary institution. PATIENTS: Patients with endometriosis of the bowel undergoing multidisciplinary resection between January 1, 2018, and October 1, 2023. MAIN OUTCOME MEASURES: A survey assessing functional outcomes on a Numeric Rating Scale preoperatively and at multiple points postoperatively. RESULTS: Of 92 eligible patients, 41 completed a preoperative survey and at least one postoperative survey. Among these 41 patients, overall pain improved postoperatively from 5.3 ± 2.7 (Numeric Rating Scale) to a nadir of 1.6 ± 1.9 at 6 months and 2.3 ± 3.0 at 12 months ( p < 0.001). Preoperative pain at ovulation (mean 4.2 Numeric Rating Scale ± 3.7), pre-period pain (4.9 ± 3.5), period pain (5.7 ± 3.6) and post-period pain (3.3 ± 3.3) all decreased to a mean of 1 at 12 months postoperatively ( p < 0.001). The proportion of patients reporting pain impacting work decreased from 88% preoperatively to <40% postoperatively ( p < 0.001). The proportion of patients happy with their bowel function increased from 39% preoperatively to 63.2% at 1 month, 80.0% at 6 months, and 69.2% at 12 months postoperatively ( p = 0.014). LIMITATIONS: Only 31.7% of patients responded to their 12-month survey, tertiary care center, low diversity in patient demographics, retrospective design. CONCLUSION: In this cohort of patients undergoing multi-disciplinary robotic excision for advanced endometriosis involving the bowel, patients reported significantly improved pain and quality of life measures. See Video Abstract.
Extended normothermic machine perfusion preserves viability and tissue integrity of ex vivo human intestine segments
Urbina, Pamela A. Manco, Choi, Sae Rome, Cheung, Dillon C., Egbert, Lena K. , Garcia-Neuer, Marlene I., Yu, Stephanie, Rehman, Nisha S., Hanks, Danielle G., Le, Tuan‐Anh , Alabay, Husnu H., McHugh, Kelsey , Hamdan, Feda H., Naik, Nimesh, Faubion, William A. , Brady, Justin T. , Ceylan, Hakan , Bose, Suman , Urbina, Pamela Allison Manco , Garcia-Neuer, Marlene , Rehman, Nabeela, Alabay, Husnu Halid , Hamdan, Feda H. , Naik, Nimesh D.

Mayo Clinic

No container title available | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.17.752436 Get It

ABSTRACT Human intestinal diseases, including inflammatory bowel disease (IBD), are difficult to model because existing animal and in vitro systems do not capture the intestine’s integrated vascular, immune, and metabolic complexity. Here, we establish a custom normothermic machine perfusion platform that maintains surgically resected human intestinal tissue for up to 72 hours under near-physiological conditions. Discarded specimens from patients with nonmalignant intestinal diseases, including IBD and diverticulitis, were continuously perfused at 37°C with real-time hemodynamic and metabolic monitoring. Perfusion preserved tissue viability, mucosal architecture, epithelial integrity, oxygen consumption, metabolic activity, and vascular patency. Daily perfusate sampling enabled longitudinal profiling and experimental modulation of inflammatory mediators, revealing patient-specific immune states. This long-duration platform bridges reductionist in vitro models and clinical disease, enabling mechanistic studies of intestinal inflammation and future testing of personalized therapies in intact patient-derived tissue.
Evaluation of lung function and airway impedance in response to ultra-marathon
Joyce, Kelsey E. , Wheatley, Courtney M. , Schwartz, Jesse C., Stewart, Glenn M., Fermoyle, Caitlin C., Taylor, Bryan J., Murdock, Robert, Constantini, Keren , Robach, Paul , Gavet, Alice , Chabridon, Loïc, Bouzat, Pierre , Johnson, Bruce D. , Joyce, Kelsey E. , Stewart, Glenn M., Tiller, Nicholas B. , Fermoyle, Caitlin C. , Murdock, Robert

Mayo Clinic

Frontiers in Physiology | August 3, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fphys.2026.1840102 | PMID 42609269 Get It

Introduction Ultra-marathon races present a prolonged cardiopulmonary physiological stress but the magnitude, persistence, and impact of race environment on respiratory function are incompletely understood. The aim of this study is to observe the effect of ultra-marathon trail races on both lung function and airway impedance. Methods Fifty-seven individuals (49/8, M/F) participated in either the Courmayeur-Champex-Chamonix (CCC ® , 101.5km), Ultra Trail du Mont-Blanc (UMTB ® , 171.5 km), or the Hong Kong 100 (HK, 100 km) races. Participant demographics were measured pre-race and included: age (40.7±10.3 yrs); height (175.5±7.1 cm), body mass (69.7±8.3 kg). Spirometry, airway impedance (via forced oscillation technique, FOT), maximal inspiratory (MIP) and expiratory pressure (MEP), and exhaled nitric oxide (ExNO) were assessed before, immediately (18–4 hours after), and 188–24 hours post-race. Mixed effects analysis with Dunnett’s post-hoc correction were conducted to evaluate the effects of race and time. Results Results demonstrated significant effects of time for: forced vital capacity (FVC), forced expiratory flow over one second (FEV 1 ), peak expiratory flow (PEF), forced expiratory flow between 25-75% (FEF25-75), forced expiratory flow at 25% and at 50% (FEF 25 and FEF 50 , respectively), MIP, MEP, airway reactance (X) at all frequencies from FOT (X 5 , X 11 , X 19 ), respiratory rate, and ExNO (all p &lt;0.05). A significant effect of race was also observed for ExNO ( p =0.002). Discussion Findings indicate declines in lung function and airway impedance immediately after ultra-marathon races, some of which, persisted up to 24 hours post-race. Further investigations are required to better understand the etiology of changes in lung function following ultra-endurance events.
Local disease control in patients with Erdheim–Chester disease treated with external beam radiation therapy
Shah, Meera , Tobin, W. Oliver , Goyal, Gaurav , Bennani, N. Nora , Kessel, Adam C , Burlile, Jessica F. , Freschette, Kelsey, Tobin, W Oliver , Goyal, Guarav , Shah, Mithun V , Bennani, N Nora , Rouse, Rachelle L, Lester, Scott C. , Abeykoon, Jithma P , Go, Ronald S , Breen, Will , Freschette, Kelsey, Rouse, Rachelle, Abeykoon, Jithma P. , Go, Ronald S. , Breen, William G.

Mayo Clinic

British Journal of Haematology | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70698 | PMID 42517545 Get It

Ambulatory antibiotic prescribing for acute sinusitis: a multicenter, retrospective cohort study evaluating appropriateness
Hannan, Kellie N. Arensman , Ilges, Dan , Le, Kimberly T. , Mara, Kristin C. , Stevens, Ryan W., Jensen, Kelsey , Arensman Hannan, Kellie , Mara, Kristin C , Jensen, Kelsey , Ilges, Dan , Le, Kimberly Thi , Stevens, Ryan W.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | June 25, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2026.10743 | PMID 42375666 Get It

Abstract Objective: Antibiotics are frequently prescribed for acute sinusitis despite national guidelines recommending antibiotics only if specific symptom criteria are met. We aimed to define the proportion of acute sinusitis encounters meeting criteria for antibiotic prescribing, characterize prescribing practices, and identify factors associated with guideline-discordant prescribing. Design: This retrospective cohort study included 1,000 randomly selected adult ambulatory encounters with a primary diagnosis of acute sinusitis between January 1, 2024 and March 31, 2024. Encounter notes were reviewed for appropriate antibiotic prescribing criteria as per national guidelines. Encounters were evaluated for drug selection and duration concordance based on local guidelines. A multivariable logistic regression analysis was performed to identify predictors of inappropriate antibiotic prescribing. Setting: Emergency departments, urgent care centers, and primary care clinics. Results: Antibiotic prescribing criteria were met for 67.6% of included encounters. Antibiotics were prescribed in 93.5% of encounters that met prescribing criteria, and 80.2% of encounters that did not. Both drug selection and duration were guideline-concordant in 49.2% of total encounters. On multivariable analysis, predictors of inappropriate antibiotic prescribing included cough (OR 2.15, 95% CI 1.08–4.29; P = 0.03) and symptom duration between 7 and 9 days (compared to <6 days; OR 7.70, 95% CI 3.24–18.31; P < 0.001). Electronic encounters were associated with lower odds of prescribing compared to in-person encounters (OR 0.03, 95% CI 0.01–0.09; P < 0.001). Conclusions: Most encounters for acute sinusitis result in an antibiotic prescription, despite prescribing criteria not being met. These findings may aid antimicrobial stewardship programs in benchmarking and optimizing antibiotic prescribing for acute sinusitis.
Pembrolizumab-induced Multifocal, Musicogenic, Autoimmune Epilepsy due to GAD65 Autoantibodies in a Patient Treated for Triple Negative Breast Cancer (P10-2.001)
Wright, Weston, Snehal, Isha , Cascino, Gregory, Pittock, Sean, Dubey, Divyanshu, Smith, Kelsey, Osman, Gamal, Cascino, Gregory D. , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215889 Get It

Sex and Gender in Neurology: A Flipped Classroom Curriculum for Trainees (P5-15.009)
Schipani, Elke , Jones, Lyell, Coon, Elizabeth, Smith, Kelsey, Jones, Lyell K. , Mustafa, Rafid

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215400 Get It

Earlier CRS identification with continuous wearable monitoring in outpatient CAR T-cell therapy.
Paludo, Jonas, Pettinati, Michael, Guo, Christine, Ruff, Michael W. , Holmes, Lucy , Haugen, Kelsey L., Amundson, Michelle, Khurana, Arushi , Bennani, Nabila Nora, Wang, Yucai, Kourelis, T., Kumar, Shaji, Kapoor, Prashant , Abdallah, Nadine, Ansell, Stephen M., Haddad, Tufia C. , Lin, Yi, Paludo, Jonas , Pettinati, Michael J. , Pritchett, Joshua C. , Holmes, Lucy M., Haugen, Kelsey, Kourelis, Taxiarchis , Kumar, Shaji , Binder, Moritz , Abdallah, Nadine , Ansell, Stephen M. , Routman, David M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1633-1633

10.1200/jco.2026.44.16_suppl.1633 Get It

1633 Background: CAR-T cell therapy has transformed outcomes of hematologic malignancies and is poised to expand into solid malignancies. However, broader use of CAR-T remains constrained by the need for timely cytokine release syndrome (CRS) detection. Current episodic monitoring may miss early physiologic changes. Wearable digital health technologies (DHTs), offering continuous monitoring and real-time alerts, could enable earlier CRS detection, further support outpatient delivery, and expand access to CAR-T and potentially other immunotherapies associated with CRS. Methods: This single-center observational study (NCT05018208) enrolled patients receiving FDA-approved CAR-T products in the outpatient setting at Mayo Clinic, Rochester MN. Management of post-CAR-T complications (e.g. CRS) followed the institution’s standard of care. Patients were monitored from day -5 to day +30 post infusion with intermittent remote patient monitoring (SoC) and an arm-worn wearable device for continuous monitoring (DHT). Patients were included in this analysis if DHT data were available for ≥ 5h of data/day or ≥ 2h of data/night on ≥2 days or nights for baseline and ≥1 day or night within 72h prior to CRS, or at least 2h within 4h of CRS onset, or if DHT was available for ≥7 days/nights post infusion with no CRS event. CRS detection time by DHT was defined as the onset of pyrexia or threshold-based deviation from an individual’s baseline pulse distributions. Results: 32 patients were included in this report (median age 64 years, gender 12 F/20 M, diagnoses 18 MM/14 NHL). 25 patients experienced a CRS event, with maximum CRS grades ranging from 1-3 (16 G1, 8 G2, 1 G3). 24/25 patients with CRS required tocilizumab/steroid. Median CRS onset time was 3.4 days (range 0.4-18.4). 12/32 patients had sufficient DHT data (7 CRS, 5 no CRS) for analysis. 5 patients with CRS had a DHT detection time in advance of the SoC by a median of 13h (range 2.8 - 69.2). The DHT prediction of CRS by baseline HR change was earlier than the first episodic fever by a median of 14.5h (range 13-77.5). The remaining 2/7 patients who did not have CRS detected by the DHT had missing DHT data for more than 45h before a treated CRS event. DHT detected CRS in 2/5 patients without CRS according to SoC. One patient had fever caught with intermittent monitoring. The other was treated for neutropenia fever with suspicion of CRS and/or infection. Conclusions: These results offer evidence that continuous DHT can identify CRS events earlier than intermittent monitoring (SoC). Despite limitations related to compliance with wearable device use and data missingness, and variability in clinical management of CRS, we highlight the usability of DHT and its potential for future studies with optimized strategies to address these limitations. Clinical trial information: NCT05018208 .